» Articles » PMID: 18063872

Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and Perspectives

Overview
Journal Onkologie
Specialty Oncology
Date 2007 Dec 8
PMID 18063872
Citations 13
Authors
Affiliations
Soon will be listed here.
Citing Articles

Celestial Insights: Unraveling the Role of miR-3682-3p in Hepatocellular Carcinoma.

Miao P, Li Y, Jiang Y Clin Transl Gastroenterol. 2024; 15(4):e00690.

PMID: 38334941 PMC: 11042776. DOI: 10.14309/ctg.0000000000000690.


Case report: An exceptional responder of low-dose continuous 5-FU in a patient with stage IV triple-negative breast cancer with liver and bone marrow failure.

Chan B, Lee J, Yuan Y Front Oncol. 2024; 13:1305584.

PMID: 38288100 PMC: 10823013. DOI: 10.3389/fonc.2023.1305584.


Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.

De Lorenzo S, Tovoli F, Barbera M, Garuti F, Palloni A, Frega G Sci Rep. 2018; 8(1):9997.

PMID: 29968763 PMC: 6030080. DOI: 10.1038/s41598-018-28337-6.


Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review.

Maur M, Omarini C, Piacentini F, Fontana A, Pettorelli E, Cascinu S Am J Case Rep. 2017; 18:208-211.

PMID: 28242865 PMC: 5340224. DOI: 10.12659/ajcr.901812.


Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases.

Marinelli S, Granito A, Piscaglia F, Renzulli M, Stagni A, Bolondi L Hepat Mon. 2013; 13(9):e11721.

PMID: 24282421 PMC: 3830515. DOI: 10.5812/hepatmon.11721.